Janssen Pharmaceutica, which is part of US healthcare giant Johnson & Johnson, plans to increase production of its Sirturo (bedaquiline) – an anti-tuberculosis drug – in Russia, at the capacities of a local drugmaker Pharmstandard, according to recent statements of the companies, reports The Pharma Letter’s local correspondent.

The Indian subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ) announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new tuberculosis (TB) treatments.

New Zealand’s Pharmaceutical Management Agency PHARMAC announced today (April 12) its decision to list cinacalcet (Sensipar) on the Pharmaceutical Schedule through an agreement with the local subsidiary of US biotech major Amgen (Nasdaq: ANGN) from May 1,2016 for: